
Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations
07/07/2025
0:00
23:00
Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.
D'autres épisodes de "CME in Minutes: Education in Dermatology"
Ne ratez aucun épisode de “CME in Minutes: Education in Dermatology” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.